NCT00987506已完成不适用
Evaluation of a XIENCE V® Endoprothesis Used for Coronary Angioplasty, for LPPR (List of Reimbursable Products and Services) Indications in Patients Monitored for 2 Years in France
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,165
- 试验地点
- 57
- 主要终点
- Occurrence rate of new revascularisation (by a new angioplasty or coronary bypass) of the lesion(s) that had received the XIENCE V® endoprothesis, one year after its implantation.
研究概览
简要总结
The objective of this study is to prepare elements of response to the Haute Autorité de Santé (High Health Authority) of France, which is expecting data relating to the routine use of XIENCE V® endoprothesis within the 5 years following its marketing.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients enrolled in the study must :
- •be at least 18;
- •be covered by Social Security
- •agree to be enrolled in the study (sign the informed consent after reading the information letter).
- •In addition, the Xience V endoprothesis implantation must be performed following the LPPR indications here under :
- •Treatment of coronary heart disease attributable to de novo lesions (reference vessel with a 2.5 to 3.5 mm) of native coronary arteries, solely in the following groups of patients :
- •patients with diabetes ;
- •lesions of small vessels (diameter < 3 mm);
- •long lesions (longer than 15 mm) ;
- •stenosis of proximal anterior intraventricular septum .
- •The use of the Xience V stent is limited to one per patient, except :
- •in case of acute occlusive dissection where three stents, maximum, may be covered ;
- •for the pluritroncular diabetic patient, in case a bypass is contra-indicated : a stent per artery, with a limit of three per patient, may be covered.
排除标准
- •Pregnant women
- •Patients with:
- •a non cardiac vital prognosis endangered during the year following the implantation ;
- •less than 72 hours myocardial infarction ;
- •lower left ventricular ejection fraction < 30 % ;
- •an allergy to the platelets antiaggregant treatment, to heparin, chrome cobalt alloy, or to the angiography contrast medium ;
- •a stenosis of the unprotected common trunk;
- •a lesion with calcifications that cannot be pre-dilated;
- •a thrombus that can be detected by angiography on the lesion to be treated ;
- •an intra-stent re-stenosis.
- •Are also excluded :
- •patients having had an angioplasty with implantation of an endoprothesis on the same vessel;
- •patients having had an angioplasty with implantation of an endoprothesis during the 6 previous months ;
- •Patients unable to keep a treatment associating aspirin and thiénopyridines for at least 6 months;
- •Patients residing abroad or who cannot be monitored according to the modalities of the study ;
- •Patients unable to give on their own free will their informed consent ; On the other hand, in absence of clinical validation, the other sub-groups of at risk patients (notably bifurcation lesions and pluritroncular lesions) cannot be considered , taken alone, as indications for the use of Xience V.
结局指标
主要结局
Occurrence rate of new revascularisation (by a new angioplasty or coronary bypass) of the lesion(s) that had received the XIENCE V® endoprothesis, one year after its implantation.
时间窗: 1 year
次要结局
- Determine the occurrence rate of new revascularisation(s) after endoprothesis implantation(18 and 24 months)
- Determine the occurrence rate of Major Cardiac Events(6, 12, 18 and 24 months)
- Determine the occurrence rate of stent thrombosis as defined by the Academic Research Consortium(6, 12, 18 and 24 months)
- The occurrence rate of death of cardiac origin(6, 12, 18 and 24 months)
- Determine the occurrence rate of myocardial infarction(6, 12, 18 and 24 months)
研究者
研究点 (57)
Loading locations...
相似试验
已完成
4 期
SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)Coronary DiseaseCoronary RestenosisCoronary Artery DiseaseNCT01171820Abbott Medical Devices324
已完成
4 期
SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in EuropeCoronary Artery DiseaseCoronary DiseaseCoronary RestenosisNCT00402272Abbott Medical Devices2,700
已完成
不适用
Clinical Validation Study of the Eximis CS (Contained Segmentation) SystemLaparoscopic Gynecological Surgical ProceduresNCT06572163Eximis Surgical23
已完成
不适用
Evaluation of Effectiveness and Safety of XIENCE PRIME Stent (IRIS-PRIME)Coronary Artery DiseaseNCT01348399Seung-Jung Park2,000
进行中（未招募）
不适用
Efficacy of a Dental Implant System for Immediate RestorationMissing TeethNCT06651502Harvard Medical School (HMS and HSDM)30